Essex Bio-Technology Ltd/ KYG312371035 /

9/29/2023 10:08:20 AM	Chg. +0.04	Volume	Bid10:08:21 AM	Ask10:08:21 AM	High	Low
2.86HKD	+1.42%	63,000 Turnover: 178,960	2.86Bid Size: 20,000	2.90Ask Size: 1,000	2.86	2.81

GlobeNewswire 3/29/2019 AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference

GlobeNewswire 3/21/2019 AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

GlobeNewswire 3/4/2019 AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress

GlobeNewswire 2/20/2019 AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer...

GlobeNewswire 2/7/2019 AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development

GlobeNewswire 1/3/2019 AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer

GlobeNewswire 12/19/2018 AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership

GlobeNewswire 12/7/2018 In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away

GlobeNewswire 11/15/2018 AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study ...

GlobeNewswire 11/13/2018 AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update

GlobeNewswire 11/1/2018 AC Immune to Present at 2018 Society for Neurosciences Meeting

GlobeNewswire 10/22/2018 AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence

GlobeNewswire 9/19/2018 Antibody Discovery Services and Platforms Market, 2028

GlobeNewswire 8/20/2018 AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Dow...

GlobeNewswire 8/8/2018 AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update

GlobeNewswire 7/25/2018 New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong ...

GlobeNewswire 7/17/2018 Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Te...

GlobeNewswire 7/6/2018 AC Immune Announces Results of Annual General Meeting

GlobeNewswire 5/2/2018 AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire 4/27/2018 AC Immune Announces Results of Extraordinary Shareholders Meeting

GlobeNewswire 4/5/2018 AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's dis...

GlobeNewswire 3/20/2018 AC Immune reports full-year 2017 financial results - successful first year as a public company

GlobeNewswire 3/15/2018 AC Immune prepares for a first in human study of a promising positron emission tomography (PET) trac...

GlobeNewswire 2/6/2018 AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Con...

GlobeNewswire 12/1/2017 AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Tar...